## **TwelveStone Health Partners** Fax Referral To:(800) 223-4063

Direct Phone: (615) 278-3350



Toll Free: (844) 893-0012

BRIUMVI ORDER FORM							
Date: ICD-10 Code:			ICD-10 Code:			Therapy Status New Start	
Patient Name: Allergies:			Allergies:				
Date of Birth: W			Weight:Ibs_ORkg		Continuing Therapy: Last Dose:		
			er Information				
Ordering Provider:				Provider Fax:	Provider Fax:		
Provider NPI:				Provider Address:_	Provider Address:		
Provider Phone:							
MEDICATION ORDER							
		First Infusion: Administer Briumvi x one dose. Infuse at 10mL/hour increase to 20mL/hr x 30 minutes 35mL/hr x 1 hour; if tolerated, the for the remaining two hours. Infus	150mg IV over 4 hours x 30 minutes; if tolerated, ; if tolerated, increase n increase 100mL/hr sion duration: 4 hours.			Please include the following lab results required for infusion. If no results are available, the following labs will be drawn prior to first infusion:	
		Second Infusion: Administer Briur hour two weeks after first infusion minutes; if tolerated, then increas remaining 30 minutes. Infusion d	e 400mL/hr for the				
□ Briumvi		Maintenance Infusions: Administ one hour 24 weeks after the first weeks thereafter. Infuse at 100n tolerated, then increase 400mL/r minutes. Infusion duration: 1 hou	er Briumvi 450mg IV over infusion and every 24 nL/hr x 30 minutes; if ir for the remaining 30 ur.	Refills x one year from signature unless indication		<ul> <li>✓ Hepatitis B Surface Antigen.</li> <li>✓ Hebatitis B Core Antibody Total (Not Core IgM).</li> <li>✓ Quantitative Serum Immunoglobulin Screening (Prior to initiation phase of treatment)</li> </ul>	
	~	Pre-medications will be given as designated otherwise. Antihistam determined by on site provider if	ine dosage and route to be	ReRe	≷efills		
	~	Pregnancy test prior to each infu reproductive potential.	sion for females of				
	~	Patient will be observed for at least one hour after first two infusions. Post-infusion monitoring of subsequent infusions is at physician discretion unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion.					
PRE-MEDICATIONS							
<u>Oral</u>	ətan	ninophen: 325mg	500mg X 650mg	<u>_IV</u>	<u>_IV</u>		
□ Loratadine:10mg					Dexamethasone: 4mg 8mg		
☐ Cetirizine:10mg					<ul> <li>✓ Diphenhydramine:25mg50mg</li> <li>□ Famotidine: 20mg40mg</li> </ul>		
✓ Diphenhydramine: 25mg50mg					✓ Methylprednisolone:125mg		
☐ Famotidine: 20mg40mg					□ Hydrocortisone:100mg		
☐ Ibuprofen: 200mg400mg600mg					☐ Ondansetron: 4mg 8mg		
Ondansetron:4mg8mg					☐ Other: 0 0		
□ Other:							
LAB ORDERS (please indicate any labs to be drawn and frequency)							
					(Please fax this signed order form, along with the following documents to 800-223-4063)		
**Surveillance lab ordering and monitoring is the responsibility of the prescriber**				Patient Demo     Medication Lis     Recent Lab W			
	<u> </u>	above therapy is med			er's Signature (SIGN BELOW)		
Dispense as Written:				Substitution Allo	Substitution Allowed:		
Prescriber N	lam	e	Date	Prescriber Name	Prescriber Name Date		
V 11.22.23							